RxDoctor Payments Data

Ashlee Robinson, MD

Family Medicine · London, KYNPI 1518133859

Payments from drug & device makers

$2,385in general payments, 2019–2025

Across 147 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$413
  • Vanda Pharmaceuticals Inc.$313
  • Novo Nordisk$272
  • Lundbeck LLC$254
  • Teva Pharmaceuticals USA, Inc.$199
  • Otsuka America Pharmaceutical, Inc.$166
  • plus $768 from 15 others

What the payments were for

  • Food & beverage$2,385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,385 in reported general payments places this provider in the 70th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$546
Medicare patients
37
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$109,009
MounjaroTirzepatide94$98,647
EliquisApixaban81$75,726
JanuviaSitagliptin Phosphate60$61,923
JardianceEmpagliflozin45$56,728
LinzessLinaclotide67$42,648
CreonLipase/Protease/Amylase12$25,798
TrulicityDulaglutide23$23,634
Nurtec OdtRimegepant Sulfate12$22,090
RybelsusSemaglutide13$18,006
Spiriva HandihalerTiotropium Bromide13$6,882
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,475
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,131
Naproxen18$3,713
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$3,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$272$127,016119 claims
Lilly USA, LLCMounjaro, Trulicity$132$122,281117 claims
AbbVieLinzess, Creon$142$68,44679 claims
MerckJanuvia$32$61,92360 claims
GSKAnoro Ellipta$15$5,47512 claims
AstraZenecaSymbicort$29$2,70612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in London

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →